Current therapy of ovarian carcinoma: an overview.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  Seminars in Oncology

• Publication date

  1985-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 4048976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radiotherapeutic management of ovarian cancer.

  1984cited by this paper
• Chemotherapy of ovarian cancer.

  1984cited by this paper
• The use of intraperitoneal chemotherapy in the treatment of ovarian cancer.

  1984cited by this paper
• A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma

  1983cited by this paper
• Chemoimmunotherapy in the management of primary stage III ovarian cancer: a Gynecologic Oncology Group study.

  1979cited by this paper
• Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

  1978cited by this paper

• Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo

  2008cites this paper
• Characterization of a c/s-Diamrninedichloroplatinum(II)-resistant Human Ovarian Cancer Cell Line and Its Use in Evaluation of Platinum Analogues1

  2006cites this paper
• Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo

  2004cites this paper
• Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432

  2004cites this paper
• Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.

  2003cites this paper
• Functional polymers in drug delivery: carrier-supported CDDP (cis-platin) complexes of polycarboxylates — effect on human ovarian carcinoma

  1998cites this paper
• Patterns of care for women with ovarian cancer in the United States.

  1997cites this paper
• Gemcitabine in cisplatin-resistant ovarian cancer.

  1996cites this paper
• Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.

  1995cites this paper
• Innovative Antimetabolites in Solid Tumours

  1994cites this paper
• Gemcitabine in Ovarian Cancer

  1994cites this paper
• 32P following negative second-look laparotomy for epithelial ovarian cancer.

  1993cites this paper
• External beam radiotherapy in the management of ovarian carcinoma.

  1993cites this paper
• Tumor debulking followed by immediate combination chemotherapy in advanced ovarian carcinoma: Phase II

  1992cites this paper
• A study of decreasing drug-resistance of human ovarian cancer cellsin vitro

  1992cites this paper
• Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.

  1991cites this paper
• Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study.

  1991cites this paper
• Intraperitoneal chemotherapy and immunotherapy.

  1991cites this paper
• Intraperitoneal cytosine arabinoside administered in sequence with systemic cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.

  1990cites this paper
• Ovarian cancer.

  1990cites this paper
• Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin

  1990cites this paper
• Whole‐abdomen radiation therapy in ovarian carcinoma: its role as a salvage therapeutic modality

  1990cites this paper
• First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.

  1989cites this paper
• The prognostic value of post chemotherapy serum CA 125 in epithelial ovarian cancer

  1989cites this paper
• The feasibility of early administration of combination chemotherapy following cytoreductive surgery and second-look operation in patients with stage III ovarian carcinoma: a pilot study.

  1989cites this paper
• Whole‐abdomen radiation therapy in ovarian carcinoma: its role as a salvage therapeutic modality

  1989cites this paper
• Chemotherapy in ovarian carcinoma.

  1989cites this paper
• Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

  1989cites this paper
• Whole abdominal irradiation following chemotherapy in advanced ovarian carcinoma.

  1988cites this paper
• The Mechanism of Acquired Resistance to Cisplatin by a Human Ovarian Cancer Cell Line

  1988cites this paper
• Antitumor activity against human tumor samples of cis-diamminedichloroplatinum(II) and analogues at equivalent in vitro myelotoxic concentrations.

  1988cites this paper
• [Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II].

  1987cites this paper
• Chemotherapy for advanced or recurrent gynecologic cancer

  1987cites this paper
• Biologic therapy for the treatment of malignant common epithelial tumors of the ovary

  1987cites this paper
• Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

  1987cites this paper
• Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

  1987cites this paper